Investigating side effects of a new tuberculosis prevention treatment in Uganda
Official title: Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy
Funded at Infectious Diseases Institute · NIH-11142468 · Data updated 2026-11-12
This study is looking at how safe a new tuberculosis prevention treatment is for adults and kids in Uganda, and it will help us understand who might have side effects while taking it, so we can make sure more people can complete their treatment successfully.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Infectious Diseases Institute NIH-funded |
| Lab location | 1 site (Kampala, Uganda) |
| Project start | May 10, 2021 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $143,543 |
| NIH project number | 5R01AI160434-05 |
| Project ID | NIH-11142468 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include adults and children over 2 years old who are starting tuberculosis preventive therapy with rifapentine and isoniazid.
✕Less likely to help
Patients who are not starting this specific tuberculosis prevention treatment or those with contraindications to rifapentine or isoniazid may not benefit from this research.
What this research studies
This research focuses on understanding the safety and side effects of a new tuberculosis prevention treatment called rifapentine combined with isoniazid, which is being rolled out in Uganda. The study will involve enrolling 614 adults and children who will receive this treatment, and they will be monitored for any adverse drug reactions over several months. By identifying which patients are more likely to experience side effects, the research aims to improve treatment completion rates and overall tuberculosis control. Participants will undergo regular evaluations, including questionnaires and laboratory tests, to assess their health during the treatment period.
Why it matters
Potential benefit: If successful, this research could lead to safer tuberculosis prevention strategies and improved health outcomes for patients receiving treatment.
How similar studies have gone: Previous research has shown that similar approaches to monitoring drug safety in tuberculosis treatments can yield valuable insights, although this specific combination is being evaluated in a new context.
Where this research is happening
-
Infectious Diseases Institute
Kampala, Uganda Active
Researchers
- Principal investigator: Sekaggya-Wiltshire, Christine — Infectious Diseases Institute
- Study coordinator: Sekaggya-Wiltshire, Christine
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.